JAMA Articles Assess Nucleic Acid West Nile Virus Screening Programs
This article was originally published in The Gray Sheet
Executive Summary
Screening individual blood donations for West Nile Virus in high-prevalence regions using nucleic acid amplification test kits identifies low level infections missed by pooled sample testing, according to two studies in the Journal of the American Medical Association
You may also be interested in...
FDA Clears Fully Automated West Nile Virus Platform
Novartis can now sell its Procleix Tigris automated testing platform at commercial pricing levels to facilities screening blood for West Nile Virus following FDA clearance March 2
FDA Clears Fully Automated West Nile Virus Platform
Novartis can now sell its Procleix Tigris automated testing platform at commercial pricing levels to facilities screening blood for West Nile Virus following FDA clearance March 2
Roche, Gen-Probe WNV Study Sites Begin Screening Under IND Approval
FDA is consulting with the Office of the Chief Counsel regarding potential legal issues related to institutional review board approval of clinical trial sites participating in West Nile Virus IND studies